Danaher Corporation
DHR
$181.35
+0.14%
Danaher Corporation is a global science and technology leader focused on manufacturing scientific instruments, consumables, software, and services for the life sciences and diagnostics industries, following its strategic divestiture of its environmental and applied solutions segment in late 2023. The company is a premier player known for its disciplined Danaher Business System (DBS) operational framework, which drives continuous improvement and has historically enabled successful integration of acquisitions to build a dominant portfolio in bioprocessing, genomics, and diagnostics. The current investor narrative is dominated by the stock's significant underperformance relative to the market, down over 36% from its 52-week high, and the strategic acquisition of Masimo's consumer health business, which is viewed as a steady but not transformative deal, as the market debates the company's growth trajectory in a post-pandemic environment characterized by a prolonged bioprocessing inventory correction.…
DHR
Danaher Corporation
$181.35
Related headlines
Investment Opinion: Should I buy DHR Today?
Rating & Thesis: Hold. Danaher is a high-quality company in a cyclical downturn, where the risk of further earnings disappointment is balanced by a compelling long-term valuation entry point for patient investors. The consensus analyst view is bullish with a 24% upside target, but near-term catalysts are lacking.
Supporting Evidence: The stock trades at a forward PE of 19.5x, which is reasonable for its quality but not deeply discounted given the growth concerns. Revenue growth is modest at 4.6% YoY, and profitability is volatile, with net margin recovering to 14.7% in Q4 after a low of 9.3%. However, the balance sheet is a fortress with a 1.87 current ratio and $5.26B in TTM FCF, and the stock trades near the bottom of its historical valuation range (P/B of 3.08). The implied 24% upside to the average analyst target is the strongest positive data point.
Risks & Conditions: The two biggest risks are a prolonged bioprocessing slump and multiple compression if growth stalls. This Hold rating would upgrade to a Buy if the forward PE compresses below 18x (price ~$207) on sustained earnings growth, or if quarterly revenue growth reaccelerates above 8% YoY. It would downgrade to a Sell if the stock breaks below its 52-week low of $160.93 on worsening fundamentals. Relative to its own history and the growth uncertainty, the stock is currently fairly valued, not clearly overvalued or undervalued.
Sign up to view all
DHR 12-Month Price Forecast
The AI assessment is neutral based on conflicting signals: compelling valuation support versus unclear near-term growth catalysts. The stock appears to be in a 'show me' phase. The strong cash flow and low leverage limit catastrophic downside, but the premium sales multiples remain vulnerable if the bioprocessing recovery is delayed. The stance would upgrade to bullish on evidence of sustained order growth in the life sciences segment or a decisive break above the $190 resistance level. It would turn bearish on a breakdown below the $161 support, signaling the downturn has further to run.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $235.75 and implied upside of +30.0% versus the current price.
Average Target
$235.75
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$145 - $236
Analyst target range
Danaher is covered by 7 analysts, indicating solid institutional coverage for this large-cap stock. The consensus sentiment leans bullish, with recent institutional ratings from firms like JP Morgan (Overweight), Jefferies (Buy), TD Cowen (Buy), and Guggenheim (Buy) affirming positive outlooks, though Wells Fargo maintains an Equal Weight rating. The average target price implied by the estimated EPS of $11.50 and a forward PE of 19.5x suggests a target near $224, which would represent approximately 24% upside from the current price of $180.1, signaling analysts see significant recovery potential. The target range, derived from estimated EPS, shows a low of $11.34 and a high of $12.13, translating to price targets of roughly $221 to $236 based on the forward PE multiple. The high target likely assumes successful execution on the Masimo integration, a resolution of the bioprocessing inventory headwinds, and multiple expansion back towards historical norms. The low target likely prices in prolonged end-market softness, margin pressure, and execution risks on acquisitions. The relatively tight EPS range ($11.34 to $12.13) suggests analysts have clustered expectations, but the wide implied price outcome stems from uncertainty over the appropriate multiple. The recent ratings activity shows stability, with no downgrades in the provided data, indicating analyst patience with the turnaround story despite the stock's poor performance.
Bulls vs Bears: DHR Investment Factors
The evidence currently tilts bearish, given the stock's severe underperformance, earnings volatility, and the unresolved bioprocessing headwind that has driven the 36% decline from its high. However, compelling bullish factors exist, primarily the strong balance sheet, significant analyst upside, and valuation now sitting at more reasonable levels. The single most important tension in the investment debate is the timing and magnitude of the bioprocessing recovery. If inventory destocking ends and growth reaccelerates sooner than expected, the forward earnings multiple of 19.5x will prove cheap, driving a sharp rally. If the correction persists into 2027, the current valuation remains vulnerable, and the stock could retest its 52-week low.
Bullish
- Strong Balance Sheet & Cash Flow: Danaher's debt-to-equity ratio of 0.35 is low, indicating minimal financial leverage risk. The company generated $5.26 billion in TTM free cash flow, providing ample liquidity for dividends, buybacks, and strategic M&A like the Masimo acquisition.
- Analysts See Significant Upside: The consensus analyst target, implied by a forward PE of 19.5x and estimated EPS of $11.50, is near $224. This represents a 24% upside from the current price of $180.1, with 4 out of 7 recent ratings being Buy or Overweight.
- Valuation Near Historical Lows: The stock trades at a forward PE of 19.5x, down from a trailing PE of 44.8x and historical peaks above 60x. Its price-to-book ratio of 3.08 is near the lower end of its recent historical range, suggesting pessimism is priced in.
- Robust Profitability Margins: Despite earnings volatility, Q4 2025 operating margin was 21.0% and gross margin was 58.0%. This demonstrates the underlying strength of its high-margin business model in life sciences and diagnostics.
Bearish
- Severe Underperformance vs. Market: DHR is down 12.2% over the past year, underperforming the S&P 500 by approximately 35 percentage points. Over six months, it's down 20.4%, indicating persistent fundamental and sentiment headwinds.
- Earnings Volatility & Margin Pressure: Net income swung from $954M in Q1 2025 to $555M in Q2 2025 before recovering to $1.20B in Q4 2025. This 42% quarterly swing highlights operational instability, particularly in the bioprocessing segment.
- Elevated Valuation Multiples: Despite the decline, the trailing PE of 44.8x remains high, and the PS ratio of 6.59 and EV/Sales of 5.73 command a premium versus many industrial peers, leaving room for further multiple compression if growth disappoints.
- Prolonged Bioprocessing Inventory Correction: The core investor narrative centers on a prolonged downturn in bioprocessing end-markets post-pandemic. This inventory correction has directly pressured revenue growth, which was only 4.6% YoY in Q4 2025.
DHR Technical Analysis
Danaher is entrenched in a significant downtrend, with the stock price down 20.4% over the past six months and 12.2% over the past year, starkly underperforming the S&P 500, which is up 22.9% over the same one-year period. Currently trading at $180.1, the stock sits just 12% above its 52-week low of $160.93 and is 26% below its 52-week high of $242.8, positioning it in the lower quartile of its yearly range and suggesting it is being priced for significant fundamental challenges rather than momentum. Recent momentum shows a modest rebound, with the stock up 8.5% over the past month, but this follows a sharp decline and conflicts with the negative 3-month return of -3.9%, indicating the recent strength is likely a technical bounce within a broader bearish trend, supported by a beta of 0.83 which implies lower volatility than the broader market. The key technical levels are clearly defined, with the 52-week high of $242.8 acting as formidable resistance and the 52-week low of $160.93 providing critical support. A decisive break below this support level would signal a continuation of the downtrend and potentially open the door to further losses, while a sustained move above the recent recovery high near $190 would be necessary to suggest a meaningful reversal is underway. The stock's beta of 0.83 indicates it is approximately 17% less volatile than the S&P 500, which is notable for a large-cap industrial but may be providing less downside cushion than expected given the magnitude of its decline; the maximum drawdown of -33.1% highlights the severe risk that has materialized for investors over this period. The price action shows the stock has been in a consistent downtrend since its peak near $242 in January 2026, with a sharp sell-off in late March and April taking it to a low near $161 in mid-May. The subsequent bounce to the $180-$190 range represents a consolidation phase, but the stock remains well below its 200-day moving average (implied by the trend). Volume data is not explicitly provided in the key metrics, but the provided average volume of 3.13 million shares suggests consistent institutional interest, likely reflecting ongoing portfolio rebalancing as the growth narrative has shifted.
Beta
0.83
0.83x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
-9.8%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | +12.0% | +1.5% |
| 3m | -5.3% | +13.4% |
| 6m | -19.2% | +10.9% |
| 1y | -9.8% | +24.5% |
| ytd | -21.3% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows modest growth but significant volatility in profitability. For Q4 2025, revenue was $6.84 billion, representing a 4.6% year-over-year increase from the $6.54 billion reported in Q4 2024. However, examining sequential quarterly data reveals a more mixed picture: revenue grew from $5.74B in Q1 2025 to $6.84B in Q4 2025, but net income margins have fluctuated significantly, from 16.6% in Q1 2025 to a low of 9.3% in Q2 2025 before recovering to 17.5% in Q4 2025, indicating underlying operational pressures, particularly in the bioprocessing end-markets. Profitability remains strong on an absolute basis, with the company reporting a net income of $1.20 billion and a net margin of 14.7% for the latest quarter. Gross margin for Q4 2025 was a robust 58.0%, consistent with its high-margin business model, though it has varied between 58% and 66.6% over the past year. The operating margin was 21.0% for the latest period, demonstrating the company's ability to convert sales to operating profit efficiently, but the significant quarter-to-quarter swings in net income (from $555M in Q2 to $1.20B in Q4) point to non-operating items and potential one-time charges impacting bottom-line consistency. The balance sheet is a source of strength, with a healthy current ratio of 1.87 and a conservative debt-to-equity ratio of 0.35, indicating low financial leverage. The company generated substantial free cash flow of $5.26 billion on a trailing twelve-month basis, providing ample liquidity for dividends, share repurchases, and strategic acquisitions like Masimo. Return on equity (ROE) is a modest 6.9%, which is low for a company of Danaher's caliber and reflects the earnings pressure from the recent downturn, but its strong cash generation and solid liquidity position it to navigate the current cycle and deploy capital opportunistically.
Quarterly Revenue
$6.8B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Given Danaher's positive net income of $1.20 billion in the latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing twelve-month PE ratio is elevated at 44.8x, while the forward PE is significantly lower at 19.5x, based on estimated EPS of $11.50. This substantial gap implies the market expects a strong earnings recovery in the coming year, pricing in a normalization from recent depressed profitability. Compared to sector averages, Danaher trades at a premium on a sales basis, with a Price-to-Sales (PS) ratio of 6.59 and an EV/Sales of 5.73, which are typically high for the industrials/healthcare sector, reflecting its premium business model and margins. However, the current forward PE of 19.5x is likely more in line with or at a moderate premium to high-quality industrial peers, justified by its strong market positions in life sciences and diagnostics, though the premium may be compressed given the growth concerns. Historically, Danaher's valuation has compressed significantly from its peak. The current trailing PE of 44.8x is down from levels above 60x seen in 2024 (e.g., 60.9x in Q3 2024), but remains above the low-30s seen in late 2023. The stock's price-to-book ratio of 3.08 is near the lower end of its historical range over the past few years, which has fluctuated between approximately 2.6 and 4.6. Trading near the bottom of its own historical valuation band suggests the market has priced in considerable pessimism, potentially offering a value opportunity if the company's earnings recovery materializes as forecasted.
PE
44.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~64x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Danaher's primary financial risk is earnings volatility, not leverage. Net income swung 42% between consecutive quarters in 2025, driven by non-operating items and end-market softness in bioprocessing. While the debt-to-equity ratio of 0.35 is low, the company's elevated valuation multiples (PS of 6.59, EV/Sales of 5.73) create margin pressure risk; if revenue growth decelerates further from the current ~5% pace, these sales-based multiples could compress sharply. The company also faces integration and execution risk from the Masimo acquisition, which must deliver promised synergies to justify its cost.
Market & Competitive Risks: The stock trades at a significant premium on sales metrics compared to broader industrials, creating valuation compression risk if growth stock multiples contract further in a higher-rate environment. Its beta of 0.83 suggests it is less volatile than the market, but its -33.1% maximum drawdown shows it has not been immune to severe sector-specific selling. The competitive risk is heightened by the prolonged bioprocessing inventory correction, which could allow rivals to gain share if Danaher's customer relationships weaken during the downturn. Recent news framing the Masimo deal as 'conservative' highlights market skepticism about near-term growth catalysts.
Worst-Case Scenario: The worst-case scenario involves the bioprocessing inventory correction extending through 2027, coupled with a failure to integrate Masimo effectively, leading to margin erosion and missed earnings estimates. In this adverse scenario, the forward PE multiple could de-rate towards 15x. Applying this to the low-end analyst EPS estimate of $11.34 implies a price target near $170. A more severe bear case would see the stock break critical support and retest its 52-week low of $160.93. From the current price of $180.1, this represents a realistic downside of -5% to -11%, with a catastrophic scenario pushing losses towards -20% or more if sector sentiment sours further.
FAQ
The key risks, in order of severity, are: 1) End-Market Risk: A prolonged bioprocessing inventory correction, which has already driven a -33.1% drawdown. 2) Valuation Risk: Elevated sales multiples (PS 6.59) could compress further if growth disappoints. 3) Execution Risk: Challenges in integrating the Masimo acquisition or failing to deliver promised synergies. 4) Operational Risk: Significant quarterly earnings volatility, as seen in the 42% swing in net income in 2025, which undermines predictability.
The 12-month forecast presents three scenarios. The Base Case (50% probability) targets $210-$225, assuming a gradual recovery and the stock trading at its current forward PE near 19.5x. The Bull Case (30% probability) targets $236-$250, requiring a swift end to the bioprocessing slump and multiple expansion. The Bear Case (20% probability) sees the stock ranging from $161 to $185, involving further earnings disappointment and multiple compression. The base case is most likely, anchored by analyst EPS estimates clustering around $11.50.
DHR is fairly valued relative to its near-term prospects but potentially undervalued on a long-term basis. Its forward PE of 19.5x is reasonable for a company of its quality and is a significant discount to its own trailing PE of 44.8x. However, its Price-to-Sales ratio of 6.59 remains at a premium to many peers, reflecting its high-margin model. The market is currently pricing in a moderate earnings recovery. If that recovery accelerates, the stock is undervalued; if it stalls, the current multiple could still compress.
DHR is a good buy for a specific investor profile: a long-term, patient investor seeking a high-quality company at a reasonable valuation during a cyclical downturn. The average analyst target implies 24% upside, and the forward PE of 19.5x is much lower than its trailing 44.8x. However, it is not a good buy for short-term traders or those sensitive to volatility, given its 12-month underperformance of -35% vs. the market and ongoing uncertainty in its bioprocessing segment. The biggest risk is a further delay in the end-market recovery.
DHR is unequivocally suitable for long-term investment, not short-term trading. Its beta of 0.83 indicates lower volatility, but its recent downtrend and cyclical headwinds mean a recovery could take multiple quarters. The company's strong dividend (though low yield) and share repurchase program are geared towards long-term holders. The investment thesis hinges on the multi-year cycle in life sciences turning, which is not a short-term catalyst. A minimum holding period of 3 years is suggested to allow the operational and market cycle to play out.
